This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why AstraZeneca (AZN) Stock Will Soar Today

NEW YORK (TheStreet) -- AstraZeneca (AZN - Get Report) stock is popping in premarket trading after larger drugmaker Pfizer (PFE - Get Report) confirmed its interest in a merger and its intention to continue discussions. 

Before market open, shares of AstraZeneca had spiked 17.1% to $80.43. 

SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.

In a statement, Pfizer said it had previously offered to purchase the biopharmaceutical company in January for 46.61 British pounds (or $76.62) a share, a transaction offered in cash and stock. At the time, the offer represented a 30% premium to AstraZeneca's share price. Pfizer said AstraZeneca declined to pursue negotiations after "limited high-level discussions." However, in late April, Pfizer contacted AstraZeneca to pursue discussions "in light of recent market developments."

Must Read: Why Simpson Manufacturing (SSD) Stock Finished Higher On Friday

"The combination of Pfizer and AstraZeneca could further enhance the ability to create value for shareholders of both companies and bring an expanded portfolio of important treatments to patients," said Pfizer CEO Ian Read in a statement. "A potential combination with AstraZeneca aligns with Pfizers current structure and fully supports its existing strategy to build world-class businesses."

A possible transaction would be accretive to Pfizer's adjusted earnings in the first full fiscal year following the combination. Pfizer noted synergies could be achieved through greater capital efficiency and a more efficient tax structure. The current contemplated structure would be a new U.K.-incorporated holding company.

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AZN $63.71 -0.98%
PFE $33.53 -0.18%
AAPL $125.42 0.72%
FB $85.76 -0.04%
GOOG $520.51 -0.19%

Markets

DOW 17,619.51 +23.16 0.13%
S&P 500 2,063.12 +5.48 0.27%
NASDAQ 4,986.8670 +28.3990 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs